However, any mechanism mediated by CD-NP application resulting in alterations of IFNγ levels could be a promising start leading to treatment options for various cancer types, autoimmune diseases, chronic inflammation, and even allergic conditions that are associated with high levels of CD40, CD80, and CD86 [57–65]. The gene discussed is CD86; the disease is autoimmune disease.